Kezar Life Sciences, Inc. reported earnings results for the full year ended December 31, 2022. For the full year, the company reported net loss was USD 68.24 million compared to USD 54.63 million a year ago. Basic loss per share from continuing operations was USD 1.01 compared to USD 1.04 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.8574 USD | +0.32% | +6.52% | -9.50% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-9.50% | 62.42M | |
+8.96% | 105B | |
-1.43% | 104B | |
+4.40% | 22.94B | |
-12.15% | 22.34B | |
-4.36% | 19.25B | |
-39.98% | 17.08B | |
-10.04% | 16.96B | |
+6.79% | 14.16B | |
+38.61% | 12.63B |
- Stock Market
- Equities
- KZR Stock
- News Kezar Life Sciences, Inc.
- Kezar Life Sciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022